F4LAB
Back to library
GH Secretagogue

Tesamorelin (5 mg Vial)

Synthetic N-terminally modified analog of human growth hormone-releasing hormone (GHRH). Studied for selective visceral adipose tissue reduction and pulsatile GH stimulation.

Vial

5 mg vial

Category

GH Secretagogue

Research highlights

A stabilized GHRH analog studied for pulsatile GH stimulation.
Clinical trials in HIV-associated lipodystrophy report reductions in visceral adipose tissue.
Preserves the physiologic GH feedback loop, unlike exogenous recombinant GH.

How this works

Tesamorelin is a stabilized GHRH analog that binds GHRH receptors on pituitary somatotrophs, stimulating synthesis and pulsatile release of endogenous growth hormone. The trans-3-hexenoyl modification enhances resistance to enzymatic degradation, extending half-life relative to native GHRH. Clinical trials in HIV-associated lipodystrophy demonstrate significant reductions in visceral adipose tissue, triglycerides, and liver fat, with effects that reverse upon discontinuation. Unlike exogenous recombinant GH, tesamorelin preserves the physiologic GH feedback loop, avoiding sustained supraphysiological IGF-1 elevation.

Storage

  • Lyophilized: store at 2–8 °C (refrigerator); for extended storage, freeze at −20 °C (−4 °F) in dry, dark conditions.
  • Reconstituted: refrigerate at 2–8 °C; use within 14–28 days; avoid freeze–thaw cycles.
  • Allow vials to reach room temperature before opening to reduce condensation.

Research-use notice

⚠️ All peptides on this site are not FDA approved and are not approved for human use outside of a clinical trial. f4Labs presents this material as a research reference only — not medical advice, diagnosis, or treatment guidance.

Peer-Reviewed References

Mechanism descriptions and research context are informed by the following published literature. Click any citation to view the source.

  1. 1
    Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. doi:10.1056/NEJMoa063306.View source
  2. 2
    Falutz J, et al. Long-term safety and efficacy of tesamorelin in HIV patients with abdominal lipohypertrophy. AIDS. 2012. doi:10.1097/QAD.0b013e3283518e6f.View source
  3. 3
    Stanley TL, et al. Effects of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients with abdominal fat accumulation: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2011. doi:10.1210/jc.2010-2227.View source